glp-1 sleep apnea trial FDA's First Approval for May Reduce Reliance on CPAP GLP-1 therapies reduce OSA risk

It works by mimicking the GLP-1 hormone to increase insulin secretion, decrease glucagon release, and slow gastric emptying

Boehringer Ingelheim International GmbH

Why injectables still lead Orals face structural constraints that injectables largely bypass: Bioavailability and dosing efficiency: peptide GLP-1s are intrinsically hard to deliver orally at high potency without formulation tradeoffs

With simplified dosing and improved convenience, these treatments reduce barriers that once delayed initiation

The FDA-approved semaglutide comes in injectable pens, but most of the compounded drug is distributed in a vial with a syringe, making it easier to measure in smaller increments